Semaglutide to be evaluated for significant fibrosis in obese and T2DM patients with NAFLD
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Abstract
Open-label clinical trial to evaluate oral Semaglutide for significant fibrosis due to NAFLD in obese or T2DM patients.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
